ReachMD takes an in-depth look at diabetes, a disease identified in nearly 1 in 10 Americans, which upsets the lives of millions more. Even more disturbing, the rates of new cases of diagnosed diabetes have risen almost twofold during the past decade. Nutrition, exercise and genetics are all factors in how the disease affects children, adults and the elderly, but that's only the beginning. How are surgical options changing the way we think about the disease? How close are we to a cure for Type 1 diabetes? Are there treatment lessons we can take from community-based initiatives abroad? Tune in to gain insights for your practice.
Host: John Anderson, MD Host: John Buse, MD, PhD Host: Carol Wysham, MD The wintertime presents new challenges for patients with chronic diseases, spe...
Host: Linda Bernstein, Pharm.D. In this episode of The Drug Report, pharmacist Dr. Linda Bernstein highlights some diabetes medications that have achi...
Host: Linda Bernstein, Pharm.D. On this episode of The Drug Report, pharmacist Dr. Linda Bernstein focuses on a recent CVS Health announcement of thei...
Host: Janine Austin Clayton, MD Guest: A. Paul Chous, MA, OD, FAAO, CDE Guest: Anne Peters, MD When it comes to protecting the vision of our patients ...
Guest: Michael H. Davidson, MD Tune in as Dr. Michael Davidson, a preventive cardiologist from the University of Chicago Pritzker School of Medicine, ...
Host: Jennifer Caudle, DO Guest: Christie Ballantyne, MD With the number of patients with both type 2 diabetes and established cardiovascular disease ...
Host: Jennifer Caudle, DO Guest: Mikhail Kosiborod, MD Guest: Christie Ballantyne, MD Since type 2 diabetes and cardiovascular disease often go hand i...
Host: Jennifer Caudle, DO Guest: Mikhail Kosiborod, MD Type 2 diabetes and established cardiovascular disease continues to impact patients and more fo...
Host: Barnett Mennen, MD Guest: Sarah Hallberg, MD Carbohydrates are our main source of energy and provide important nutrients for good health. Howeve...
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, ...